Chicago Equity Partners’s Theravance Biopharma TBPH Stock Holding History

Chicago Equity Partners’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$1M	Sell	43,480 -27,105	-38%	-$678K	0.1%	285
2019 Q4	$1.83M	Sell	70,585 -11,375	-14%	-$221K	0.1%	294
2019 Q3	$1.6M	Buy	81,960 +28,895	+54%	+$584K	0.08%	373
2019 Q2	$867K	Sell	53,065 -200	-0.4%	-$4.05K	0.04%	562
2019 Q1	$1.21M	Sell	53,265 -595	-1%	-$15.1K	0.05%	463
2018 Q4	$1.38M	Buy	+53,860	New	+$1.45M	0.06%	421

Other funds holding TBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFS

Link Fund Solutions London, United Kingdom $157M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Chicago Equity Partners's TBPH Position: Q1 2020 in Review

Chicago Equity Partners reduced its Theravance Biopharma (TBPH) stake by 38% in Q1 2020, selling an estimated $678K and leaving 43,480 shares worth $1M. The position accounts for 0.1% of the portfolio, ranked #285.

Chicago Equity Partners first reported a position in TBPH in Q4 2018 and has held it in 6 quarters since. The position peaked at $1.83M in Q4 2019. 105 funds tracked by Wall St. Rank hold TBPH as of Q1 2020.

Chicago Equity Partners held 43,480 shares of Theravance Biopharma worth $1M as of Q1 2020.
Chicago Equity Partners sold 27,105 Theravance Biopharma shares in Q1 2020, an estimated $678K.
Theravance Biopharma made up 0.1% of Chicago Equity Partners's portfolio in Q1 2020, its #285 holding.
Chicago Equity Partners first reported a position in Theravance Biopharma in Q4 2018 and has held it in 6 quarters since.
Chicago Equity Partners's Theravance Biopharma position peaked at $1.83M in Q4 2019.
105 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.